Form 4 for KYMR Kymera Therapeutics, Inc.
Accepted 2026-03-04 00:00:00 ET · period of report 2026-03-02 · accession 0001193125-26-091983 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-03-04 | 2026-03-02+ | KYMR | Gollob Jared | Chief Medical Off | S - Sale | $87.24 | -10.5K | 117.1K | -8% | -$916.7K |
| D | 2026-03-04 | 2026-03-02 | KYMR | Gollob Jared | Chief Medical Off | A - Grant | $0.00 | +17.6K | 127.6K | +16% | $0 |
| D | 2026-03-04 | 2026-03-02 | KYMR | Gollob Jared | Chief Medical Off | A - Grant | $0.00 | +35.3K | 35.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-04 | S | D | 1,437 | $85.78 | 117,581 | D | — | — | (F8) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.45 to $86.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2026-03-04 | S | D | 492 | $84.00 | 121,537 | D | — | — | (F6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.36 to $84.3338, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2026-03-04 | S | D | 2,519 | $85.04 | 119,018 | D | — | — | (F7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.4475 to $85.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2026-03-02 | S | D | 3,048 | $89.66 | 122,029 | D | — | — | (F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.17 to $90.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 5 | Common | Common Stock | 2026-03-02 | S | D | 1,055 | $88.50 | 125,077 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.11 to $89.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 6 | Common | Common Stock | 2026-03-02 | S | D | 1,510 | $87.75 | 126,132 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.11 to $88.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 7 | Common | Common Stock | 2026-03-02 | A | A | 17,650 | $0.00 | 127,642 | D | — | — | (F1) Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date. |
| 8 | Common | Common Stock | 2026-03-04 | S | D | 447 | $86.62 | 117,134 | D | — | — | (F9) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.48 to $86.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 9 | Derivative | Stock Option (Right to Buy) | 2026-03-02 | A | A | 35,300 | $0.00 | 35,300 | D | $90.10 · — to 2036-03-01 | 35,300 Common Stock | (F10) The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date. |